Table 1. Basal characteristics of 131 patients with invasive ductal carcinoma of the breast.
| Without recurrence | With recurrence | |
|---|---|---|
| Characteristics | No. (%) | No. (%) |
| Total cases | 66 (100) | 65 (100) |
| Age (years) | ||
| ⩽58 | 32 (48.5) | 38 (58.5) |
| >58 | 34 (51.5) | 27 (41.5) |
| Menopausal status | ||
| Premenopausal | 21 (31.8) | 18 (27.7) |
| Postmenopausal | 45 (68.2) | 47 (72.3) |
| Tumoural size | ||
| T1 | 36 (54.5) | 27 (41.5) |
| T2 | 30 (45.5) | 38 (58.5) |
| Nodal status | ||
| N (−) | 34 (51.5) | 28 (43.1) |
| N (+) | 32 (48.5) | 37 (56.9) |
| Histological grade a | ||
| Well Dif. | 23 (34.8) | 13 (20) |
| Mod. Dif. | 29 (43.9) | 35 (53.8) |
| Poorly Dif. | 14 (21.2) | 17 (26.1) |
| Nottingham pronostic index | ||
| <3.4 | 29 (63) | 17 (37) |
| 3.4–5.4 | 28 (46.7) | 32 (53.3) |
| >5.4 | 9 (36) | 16 (64) |
| Estrogen receptors a | ||
| Negative | 26 (39.4) | 36 (55.4) |
| Positive | 40 (60.6) | 29 (44.6) |
| Progesterone receptors a | ||
| Negative | 27 (37.9) | 42 (64.6) |
| Positive | 39 (59.1) | 23 (35.4) |
| Adjuvant radiotherapy | ||
| No | 48 (72.7) | 33 (50.8) |
| Yes | 18 (27.3) | 32 (49.2) |
| Adjuvant systemic therapy | ||
| Chemotherapy | 20 (30.3) | 30 (46.2) |
| Adjuvant tamoxifen | 26 (39.4) | 15 (23.1) |
| Chemotherapy plus sequential tamoxifen | 11 (16.7) | 7 (10.8) |
| No treatment | 9 (13.6) | 14 (21.5) |
a
Criteria reported by Bloom and Richardson.
ER and PgR receptor measurements were performed on cytosol extracts by using a enzyme immunoassay (Monoclonal from Abbot Laboratories, Diagnostics Division, Wiesbaden, Germany). A value higher than 10 fmol mg−1 total protein was considered as positive.